Literature DB >> 22342802

Genetic variation in CYP2A6 predicts neural reactivity to smoking cues as measured using fMRI.

Deborah W Tang1, Brian Hello, Margaret Mroziewicz, Lesley K Fellows, Rachel F Tyndale, Alain Dagher.   

Abstract

Smoking cues trigger craving for cigarettes and relapse. Nicotine metabolism, mediated by the enzyme CYP2A6, also influences smoking behavior. In this study, we investigated how nicotine metabolism and genetic variation in CYP2A6 influence the neural response to smoking cues in humans using functional magnetic resonance imaging (fMRI). We hypothesized that individuals with faster rates of nicotine metabolism would have stronger conditioned responses to smoking cues because of closer coupling in everyday life between exposure to cigarettes and surges in blood nicotine concentration. In contrast, individuals with reduced rates of metabolism, who have relatively constant nicotine blood levels throughout the day, should be less likely to develop conditioned responses to cues. We screened 169 smokers for their rate of nicotine metabolism and CYP2A6 genotype, and selected 31 smokers with the fastest and slowest rates for fMRI, matched for daily cigarette intake. We measured their neural response to visual smoking and non-smoking cues using fMRI. As predicted, fast metabolizers, by phenotype or genotype, had significantly greater responses to visual cigarette cues than slow metabolizers in the amygdala, hippocampus, striatum, insula, and cingulate cortex. These results support the theory that drug cues are conditioned stimuli, and explain why fast metabolizers who smoke have lower cessation rates. They also provide insight into how genetics can shape human vulnerability to addiction, and have implications for tailoring smoking cessation programs based on individual genetics.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22342802     DOI: 10.1016/j.neuroimage.2012.01.119

Source DB:  PubMed          Journal:  Neuroimage        ISSN: 1053-8119            Impact factor:   6.556


  25 in total

Review 1.  Precision Medicine for Tobacco Dependence: Development and Validation of the Nicotine Metabolite Ratio.

Authors:  Cheyenne E Allenby; Kelly A Boylan; Caryn Lerman; Mary Falcone
Journal:  J Neuroimmune Pharmacol       Date:  2016-02-12       Impact factor: 4.147

2.  Brief Report: Rate of Nicotine Metabolism and Tobacco Use Among Persons With HIV: Implications for Treatment and Research.

Authors:  Robert A Schnoll; Morgan Thompson; Katrina Serrano; Frank Leone; David Metzger; Ian Frank; Robert Gross; Karam Mounzer; Rachel F Tyndale; Jessica Weisbrot; Miles Meline; Ronald G Collman; Rebecca L Ashare
Journal:  J Acquir Immune Defic Syndr       Date:  2019-02-01       Impact factor: 3.731

3.  Differences in the rate of nicotine metabolism among smokers with and without HIV.

Authors:  Rebecca L Ashare; Morgan Thompson; Frank Leone; David Metzger; Robert Gross; Karam Mounzer; Rachel F Tyndale; Caryn Lerman; Martin C Mahoney; Paul Cinciripini; Tony P George; Ronald G Collman; Robert Schnoll
Journal:  AIDS       Date:  2019-05-01       Impact factor: 4.177

4.  The Genetics, Neurogenetics and Pharmacogenetics of Addiction.

Authors:  Catherine H Demers; Ryan Bogdan; Arpana Agrawal
Journal:  Curr Behav Neurosci Rep       Date:  2014-03-01

5.  Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial.

Authors:  Caryn Lerman; Robert A Schnoll; Larry W Hawk; Paul Cinciripini; Tony P George; E Paul Wileyto; Gary E Swan; Neal L Benowitz; Daniel F Heitjan; Rachel F Tyndale
Journal:  Lancet Respir Med       Date:  2015-01-12       Impact factor: 30.700

6.  Novel CYP2A6 diplotypes identified through next-generation sequencing are associated with in-vitro and in-vivo nicotine metabolism.

Authors:  Julie-Anne Tanner; Andy Z Zhu; Katrina G Claw; Bhagwat Prasad; Viktoriya Korchina; Jianhong Hu; HarshaVardhan Doddapaneni; Donna M Muzny; Erin G Schuetz; Caryn Lerman; Kenneth E Thummel; Steven E Scherer; Rachel F Tyndale
Journal:  Pharmacogenet Genomics       Date:  2018-01       Impact factor: 2.089

Review 7.  Biomarkers of Response to Smoking Cessation Pharmacotherapies: Progress to Date.

Authors:  Michael Mamoun; Andrew W Bergen; Jennifer Shieh; Anna Wiggins; Arthur L Brody
Journal:  CNS Drugs       Date:  2015-05       Impact factor: 5.749

8.  The influence of nicotine metabolic rate on working memory over 6 hours of abstinence from nicotine.

Authors:  Natalie Nardone; Marian Shahid; Andrew A Strasser; Delia A Dempsey; Neal L Benowitz
Journal:  Pharmacol Biochem Behav       Date:  2019-12-05       Impact factor: 3.533

9.  Cytochrome P450 2A6 and 2B6 polymorphisms and smoking cessation success in patients treated with varenicline.

Authors:  Paulo Roberto Xavier Tomaz; Mariana Soares Kajita; Juliana Rocha Santos; Jaqueline Scholz; Tânia Ogawa Abe; Patrícia Viviane Gaya; José Eduardo Krieger; Alexandre Costa Pereira; Paulo Caleb Júnior Lima Santos
Journal:  Eur J Clin Pharmacol       Date:  2019-08-11       Impact factor: 2.953

Review 10.  Neuroimaging in psychiatric pharmacogenetics research: the promise and pitfalls.

Authors:  Mary Falcone; Ryan M Smith; Meghan J Chenoweth; Abesh Kumar Bhattacharjee; John R Kelsoe; Rachel F Tyndale; Caryn Lerman
Journal:  Neuropsychopharmacology       Date:  2013-06-24       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.